FLT3抑制剂的抗肿瘤研发现状
|
摘要
FLT3是一种受体型酪氨酸激酶,对造血细胞和淋巴细胞的增殖起关键作用。FLT3的异常激活与多种肿瘤特别是与急性髓性白血病的发生发展密切相关。以FLT3为靶点的小分子激酶抑制剂为多种肿瘤的治疗开辟了新途径,有许多FLT3抑制剂进入临床研究阶段,在靶向抗肿瘤领域有巨大的前景。本文主要对近年来的FLT3抑制剂的适应症及其研发状况进行综述。
FLT3, a receptor tyrosine kinase, plays essential roles in hemopoiesis as well as the proliferation of lymphocyte. The abnormal activated FLT3 was closely related to the development of many cancers, especially AML. As a potential target, FLT3 was intensively studied in current pharmaceutical development. Blocking FLT3 pathway provided a promising treatment for cancer. FLT3 inhibitors were registered for clinical trials, demonstrating great efficacy against cancer. This review summarized the indication of FLT3 inhibitors and their research and development status in recent years.
FLT3, a receptor tyrosine kinase, plays essential roles in hemopoiesis as well as the proliferation of lymphocyte. The abnormal activated FLT3 was closely related to the development of many cancers, especially AML. As a potential target, FLT3 was intensively studied in current pharmaceutical development. Blocking FLT3 pathway provided a promising treatment for cancer. FLT3 inhibitors were registered for clinical trials, demonstrating great efficacy against cancer. This review summarized the indication of FLT3 inhibitors and their research and development status in recent years.
引文
[1]FLT3(FMS-like tyrosine kinase 3)[EB/OL].http://atlasgeneticsoncology.org/Genes/FLT3ID144.html.
[2]Griffith J,Black J,Faerman C,et al.The structural basis for autoinhibition of FLT3 by the juxtamembrane domain[J].Mol Cell,2004,13(2):169-178.
[3]Song G,Valdez BC,Li Y,et al.Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMSlike tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells[J].Biol Blood Marrow Transplant,.2014,20(11):1687-1695.doi:10.1016/j.bbmt.2014.08.003.
[4]FLT3 Signaling[EB/OL].http://www.sabiosciences.com/pathway.phpsn=FLT3_Signaling.
[5]Hatzimichael E,Tsolas E,Briasoulis E.Profile of pacritinib and its potential in the treatment of hematologic disorders[J].J Blood Med.2014,5:143-152.doi:10.2147/JBM.S51253.
[6]Smith CC,Wang Q,Chin CS,et al.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia[J].Nature,2012,485(7397):260-263.doi:10.1038/nature11016.
[7]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
[8]Sorafenib(NEXAVAR)[EB/OL].http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm376547.htm.
[9]Rare disease(orphan)designations[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages%2Fmedicines%2Flanding%2Forphan_search.jsp&mid=WC0b01ac058001d12b&searchkw By Enter=false&already Loaded=true&is New Query=true&status=Positive&status=Negative&status=With drawn&status=Expired&start Letter=S&keyword=Sorafenib&search Type=Medicine.
[10]Strumberg D,Richly H,Hilger RA,et al.Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY43-9006 in patients with advanced refractory solid tumors[J].J Clin Oncol,2005,23(5):965-972.
[11]Lewis NL,Lewis LD,Eder JP,et al.Phase I study of the safety,tolerability,and pharmacokinetics of oral CP-868,596,a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers[J].J Clin Oncol,2009,27(31):5262-5269.doi:10.1200/JCO.2009.21.8487.
[12]O'Farrell AM,Abrams TJ,Yuen HA,et al.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo[J].Blood,2003,101(9):3597-3605.doi:10.1182/blood-2002-07-2307.
[13]Rask-Andersen M,Zhang J,Fabbro D,et al.Advances in kinase targeting:current clinical use and clinical trials[J].Trends Pharmacol Sci,2014,35(11):604-620.doi:10.1016/j.tips.2014.09.007.
[14]Rini BI,Garcia JA,Cooney MM,et al.A phase I study of sunitinib plus bevacizumab in advanced solid tumors[J].Clin Cancer Res,2009,15(19):6277-6283.doi:10.1158/1078-0432.CCR-09-0717.
[15]NEXAVAR(sorafenib)tablets,oral[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021923s015lbl.pdf
[16]Gozgit JM,Wong MJ,Wardwell S,et al.Potent activity of ponatinib(AP24534)in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies[J].Mol Cancer Ther,2011,10(6):1028-1035.doi:10.1158/1535-7163.MCT-10-1044.
[17]Australian Register of Therapeutic Goods[EB/OL].http://search-au.funnelback.com/s/search.htmlcollection=tgaartg&profile=record&meta_i=212584.
[18]Cortes JE,Kantarjian H,Shah NP,et al.Ponatinib in refractory Philadelphia chromosome-positive leukemias[J].N Engl J Med,2012,367(22):2075-2088.doi:10.1056/NEJMoa1205127.
[19]ICLUSIG(ponatinib)tablets for oral use[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s008lbl.pdf.
[20]You WK,Sennino B,Williamson CW,et al.VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer[J].Cancer Res,2011,71(14):4758-4768.doi:10.1158/0008-5472.CAN-10-2527.
[21]Rare disease designations[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/orphans/2009/11/human_orphan_000569.jsp&mid=WC0b01ac058001d12b.
[22]Search Orphan Drug Designations and Approvals:cabozantinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=297109.
[23]ANNEX I summary of product characteristics[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002640/WC500163703.pdf.
[24]Chen YB,Li S,Lane AA.Lane,et al.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia[J].Biol Blood Marrow Transplant,2014,20(12):2042-2048.doi:10.1016/j.bbmt.2014.09.007.
[25]Navis AC,Bourgonje A,Wesseling P,et al.Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2[J].PLo S One,2013,8(3):e58262.doi:10.1371/journal.pone.0058262.
[26]63 studies found for:Cabozantinib[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=Cabozantinib.
[27]COMETRIQ(cabozantinib)capsules,for oral use[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf.
[28]Kurzrock R,Sherman SI,Ball DW,et al.Activity of XL184(Cabozantinib),an oral tyrosine kinase inhibitor,in patients with medullary thyroid cancer[J].J Clin Oncol,2011,29(19):2660-2666.doi:10.1200/JCO.2010.32.4145.
[29]Poulsen A,William A,Blanchard S,et al.Structure-based design of oxygen-linked macrocyclic kinase inhibitors:discovery of SB1518 and SB1578,potent inhibitors of Janus kinase 2(JAK2)and Fms-like tyrosine kinase-3(FLT3)[J].J Comput Aided Mol Des,2012,26(4):437-450.doi:10.1007/s10822-012-9572-z.
[30]EMEA-001621-PIP01-14[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/pips/EMEA-001621-PIP01-14/pip_001217.jsp&mid=WC0b01ac058001d129.
[31]CDER Fast Track Products Approved Since 1998 through June1,2010[EB/OL].http://www.fda.gov/downloads/Drugs/Development Approval Process/How Drugsare Developedand Approved/Drugand Biologic Approval Reports/UCM216527.pdf.
[32]Zarrinkar PP,Gunawardane RN,Cramer MD,et al.AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia(AML)[J].Blood,2009,114(14):2984-2992.doi:10.1182/blood-2009-05-222034.
[33]Lancet JE.New agents:great expectations not realized[J].Best Pract Res Clin Haematol,2013,26(3):269-274.doi:10.1016/j.beha.2013.10.007.
[34]Tentler JJ,Bradshaw-Pierce EL,Serkova NJ,et al.Assessment of the in vivo antitumor effects of ENMD-2076,a novel multitargeted kinase inhibitor,against primary and cell line-derived human colorectal cancer xenograft models[J].Clin Cancer Res,.2010,16(11):2989-2998.doi:10.1158/1078-0432.CCR-10-0325.
[35]Search Orphan Drug Designations and Approvals:Midostaurin[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=306410.
[36]11 studies found for:PLX-3397[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=PLX-3397&Search=Search.
[37]Fletcher GC,Brokx RD,Denny TA,et al.ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action[J].Mol Cancer Ther,2011,10(1):126-137.doi:10.1158/1535-7163.MCT-10-0574.
[38]8 studies found for:ENMD-2076[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=ENMD-2076&Search=Search.
[39]Berdini V,Curry JE,Gallagher NJ,et al.Pharmaceutical Compounds:US,WO/2007/077435(A1)[P/OL].2007-07-12.http://www.freepatentsonline.com/WO2007077435A1.html.
[40]5 studies found for:AT-9283[EB/OL].https://clinicaltrials.gov/ct2/results/s=b&flds=i&flds=f&flds=j&submit_fld_opt=on&term=AT-9283&show_flds=Y.
[41]Heinrich MC,Griffith D,Mc Kinley A,et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors[J].Clin Cancer Res,2012,18(16):4375-4384.doi:10.1158/1078-0432.CCR-12-0625.
[42]10 studies found for:Crenolanib[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=Crenolanib&Search=Search.
[43]Heise CC,Hollenbach P,Menezes D,et al.Treatment of Melanoma:Switzerland,WO/2008/112509(A1)[P/OL].2008-09-18.http://www.freepatentsonline.com/WO2008112509A1.html.
[44]47 studies found for:Dovitinib[EB/OL].https://clinicaltrials.gov/ct2/resultsterm=Dovitinib&Search=Search.
[45]Famitinib malate VS Sunitinib malate(Sutent)[EB/OL].http://blog.sina.com.cn/s/blog_69ecff150100nf2r.html.[苹果酸法米替尼VS苹果酸舒尼替尼(索坦)[EB/OL].http://blog.sina.com.cn/s/blog_69ecff150100nf2r.html.]
[46]Zhang W,Zhou AP,Qin Q,et al.Famitinib in metastatic renal cell carcinoma:a single center study[J].Chin Med J(Engl),2013,126(22):4277-4281.doi:10.3760/cma.j.issn.0366-6999.20131757.
[47]8 studies found for:Famitinib[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=Famitinib&Search=Search.
[48]Chan WW,Wise SC,Kaufman MD,et al.Conformational control inhibition of the BCR-ABL1 tyrosine kinase,including the gatekeeper T315I mutant,by the switch-control inhibitor DCC-2036[J].Cancer Cell,2011,19(4):556-568.doi:10.1016/j.ccr.2011.03.003.
[49]Cortes JE,Talpaz M,Kantarjian HM,et al.A Phase 1 study of DCC-2036,a novel oral inhibitor of BCR-ABL kinase,in patients with philadelphia chromosome positive(Ph+)leukemias including patients with T315I mutation[J].Blood(ASH Annual Meeting Abstracts)2011;118(21):Abstract 601.
[50]Eriksson A,Kalushkova A,Jarvius M,et al.AKN-028induces cell cycle arrest,downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia[J].Biochem Pharmacol,2014,87(2):284-291.doi:10.1016/j.bcp.2013.10.022.
[51]Trial record 1 of 1 for:AKN-028[EB/OL].https://clinicaltrials.gov/ct2/show/NCT01573247term=AKN-028&rank=1.
[52]Stone RM,Fischer T,Paquette R,et al.Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia[J].Leukemia,2012,26(9):2061-2068.doi:10.1038/leu.2012.115.
[53]Trial record 1 of 1 for:NCT02014558[EB/OL].https://www.clinicaltrials.gov/ct2/show/NCT02014558term=NCT02014558&rank=1.
[54]William AD,Lee AC,Goh KC,et al.Discovery of kinase spectrum selective macrocycle(16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene(SB1317/TG02),a potent inhibitor of cyclin dependent kinases(CDKs),Janus kinase 2(JAK2),and fms-like tyrosine kinase-3(FLT3)for the treatment of cancer[J].J Med Chem,2012,55(1):169-196.doi:10.1021/jm201112g.
[55]álvarez-Fernández S,Ortiz-Ruiz MJ,Parrott T,et al.Potent antimyeloma activity of a novel ERK5/CDK inhibitor[J].Clin Cancer Res,2013,19(10):2677-2687.doi:10.1158/1078-0432.CCR-12-2118.
[56]Younes A,Romaguera J,Fanale M,et al.Phase I study of a novel oral Janus kinase 2 inhibitor,SB1518,in patients with relapsed lymphoma:evidence of clinical and biologic activity in multiple lymphoma subtypes[J].J Clin Oncol,2012,30(33):4161-4167.doi:10.1200/JCO.2012.42.5223.
[57]Furqan M,Mukhi N,Lee B,et al.Dysregulation of JAKSTAT pathway in hematological malignancies and JAK inhibitors for clinical application[J].Biomark Res,2013,1(1):5.doi:10.1186/2050-7771-1-5.
[58]Search Orphan Drug Designations and Approvals:Pacritinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=245607.
[59]Cortes JE,Kantarjian H,Foran JM,et al.Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMSlike tyrosine kinase 3-internal tandem duplication status[J].J Clin Oncol,2013,31(29):3681-3687.doi:10.1200/JCO.2013.48.8783.
[60]Ramsingh G,Westervelt P,Mc Bride A,et al.Phase I study of cladribine,cytarabine,granulocyte colony stimulating factor(CLAG regimen)and midostaurin and all-trans retinoic acid in relapsed/refractory AML[J].Int J Hematol,2014,99(3):272-278.doi:10.1007/s12185-014-1503-4.
[61]EU/3/04/214[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/orphans/2009/11/human_orphan_000072.jsp&mid=WC0b01ac058001d12b.
[62]Search Orphan Drug Designations and Approvals:Midostaurin[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=285909.
[63]Phase I data suggest PLX3397 is a potential therapy for patients with advanced pigmented villonodular synovitis[EB/OL].Memorial Sloan Kettering Cancer Center,[2014-05-14].http://www.mskcc.org/pressroom/press/phase-i-data-suggest-plx3397-potential-therapy-patients-advanced-pigmented-villonodular-synovitis.
[64]Search Orphan Drug Designations and Approvals:[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=419913.
[65]Trial record 1 of 8 for:ENMD-2076[EB/OL].https://www.clinicaltrials.gov/ct2/show/NCT01914510term=ENMD-2076&rank=1.
[66]Diamond JR,Bastos BR,Hansen RJ,et al.Phase I safety,pharmacokinetic,and pharmacodynamic study of ENMD-2076,a novel angiogenic and Aurora kinase inhibitor,in patients with advanced solid tumors[J].Clin Cancer Res,2011,17(4):849-860.doi:10.1158/1078-0432.CCR-10-2144.
[67]Search Orphan Drug Designations and Approvals:2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+)tartrate salt[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=437214.
[68]Lewis NL,Lewis LD,Eder JP,et al.Phase I study of the safety,tolerability,and pharmacokinetics of oral CP-868,596,a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers[J].J Clin Oncol,2009,27(31):5262-5269.doi:10.1200/JCO.2009.21.8487.
[69]Search Orphan Drug Designations and Approvals:Crenolanib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=363812.
[70]Search Orphan Drug Designations and Approvals:Crenolanib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=320910.
[71]Search Orphan Drug Designations and Approvals:Crenolanib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=335911.
[72]Kim KB,Chesney J,Robinson D,et al.Phase I/II and pharmacodynamic study of dovitinib(TKI258),an inhibitor of fibroblast growth factor receptors and VEGF receptors,in patients with advanced melanoma[J].Clin Cancer Res,2011,17(23):7451-7461.doi:10.1158/1078-0432.CCR-11-1747.
[73]Search Orphan Drug Designations and Approvals:Dovitinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=210105.
[74]Search Orphan Drug Designations and Approvals:dovitinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=388012.
[75]Cao J,Zhang J,Wang ZH,et al.Hypothyroidism as a potential biomarker of efficacy of famitinib,a novel VEGFR2 inhibitor in metastatic breast cancer[C].6th Asian Oncology Summit and10th Annual Conference of the Organisation for Oncology and Translational Research,Eur J Cancer,2014,50(Suppl 4):e1.
[76]Chiang AK,Mak NK,Ng WT.Translational research in nasopharyngeal carcinoma[J].Oral Oncol,2014,50(5):345-352.doi:10.1016/j.oraloncology.2013.11.005.
[77]Eriksson A,Hermanson M,Wickstrm M,et al.The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia[J].Blood Cancer J,2012,2:e81.doi:10.1038/bcj.2012.28.
[78]Poulsen A,William A,Blanchard S,et al.Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02,a potent inhibitor of cyclin dependant kinases(CDKs),Janus kinase 2(JAK2),and Fms-like tyrosine kinase-3(FLT3)[J].J Mol Model,2013,19(1):119-130.doi:10.1007/s00894-012-1528-7.
[79]Arkenau HT,Plummer R,Molife LR,et al.A phase I dose escalation study of AT9283,a small molecule inhibitor of aurora kinases,in patients with advanced solid malignancies[J].Ann Oncol,2012,23(5):1307-1313.doi:10.1093/annonc/mdr451.
[2]Griffith J,Black J,Faerman C,et al.The structural basis for autoinhibition of FLT3 by the juxtamembrane domain[J].Mol Cell,2004,13(2):169-178.
[3]Song G,Valdez BC,Li Y,et al.Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMSlike tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells[J].Biol Blood Marrow Transplant,.2014,20(11):1687-1695.doi:10.1016/j.bbmt.2014.08.003.
[4]FLT3 Signaling[EB/OL].http://www.sabiosciences.com/pathway.phpsn=FLT3_Signaling.
[5]Hatzimichael E,Tsolas E,Briasoulis E.Profile of pacritinib and its potential in the treatment of hematologic disorders[J].J Blood Med.2014,5:143-152.doi:10.2147/JBM.S51253.
[6]Smith CC,Wang Q,Chin CS,et al.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia[J].Nature,2012,485(7397):260-263.doi:10.1038/nature11016.
[7]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
[8]Sorafenib(NEXAVAR)[EB/OL].http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm376547.htm.
[9]Rare disease(orphan)designations[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages%2Fmedicines%2Flanding%2Forphan_search.jsp&mid=WC0b01ac058001d12b&searchkw By Enter=false&already Loaded=true&is New Query=true&status=Positive&status=Negative&status=With drawn&status=Expired&start Letter=S&keyword=Sorafenib&search Type=Medicine.
[10]Strumberg D,Richly H,Hilger RA,et al.Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY43-9006 in patients with advanced refractory solid tumors[J].J Clin Oncol,2005,23(5):965-972.
[11]Lewis NL,Lewis LD,Eder JP,et al.Phase I study of the safety,tolerability,and pharmacokinetics of oral CP-868,596,a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers[J].J Clin Oncol,2009,27(31):5262-5269.doi:10.1200/JCO.2009.21.8487.
[12]O'Farrell AM,Abrams TJ,Yuen HA,et al.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo[J].Blood,2003,101(9):3597-3605.doi:10.1182/blood-2002-07-2307.
[13]Rask-Andersen M,Zhang J,Fabbro D,et al.Advances in kinase targeting:current clinical use and clinical trials[J].Trends Pharmacol Sci,2014,35(11):604-620.doi:10.1016/j.tips.2014.09.007.
[14]Rini BI,Garcia JA,Cooney MM,et al.A phase I study of sunitinib plus bevacizumab in advanced solid tumors[J].Clin Cancer Res,2009,15(19):6277-6283.doi:10.1158/1078-0432.CCR-09-0717.
[15]NEXAVAR(sorafenib)tablets,oral[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021923s015lbl.pdf
[16]Gozgit JM,Wong MJ,Wardwell S,et al.Potent activity of ponatinib(AP24534)in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies[J].Mol Cancer Ther,2011,10(6):1028-1035.doi:10.1158/1535-7163.MCT-10-1044.
[17]Australian Register of Therapeutic Goods[EB/OL].http://search-au.funnelback.com/s/search.htmlcollection=tgaartg&profile=record&meta_i=212584.
[18]Cortes JE,Kantarjian H,Shah NP,et al.Ponatinib in refractory Philadelphia chromosome-positive leukemias[J].N Engl J Med,2012,367(22):2075-2088.doi:10.1056/NEJMoa1205127.
[19]ICLUSIG(ponatinib)tablets for oral use[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s008lbl.pdf.
[20]You WK,Sennino B,Williamson CW,et al.VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer[J].Cancer Res,2011,71(14):4758-4768.doi:10.1158/0008-5472.CAN-10-2527.
[21]Rare disease designations[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/orphans/2009/11/human_orphan_000569.jsp&mid=WC0b01ac058001d12b.
[22]Search Orphan Drug Designations and Approvals:cabozantinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=297109.
[23]ANNEX I summary of product characteristics[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002640/WC500163703.pdf.
[24]Chen YB,Li S,Lane AA.Lane,et al.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia[J].Biol Blood Marrow Transplant,2014,20(12):2042-2048.doi:10.1016/j.bbmt.2014.09.007.
[25]Navis AC,Bourgonje A,Wesseling P,et al.Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2[J].PLo S One,2013,8(3):e58262.doi:10.1371/journal.pone.0058262.
[26]63 studies found for:Cabozantinib[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=Cabozantinib.
[27]COMETRIQ(cabozantinib)capsules,for oral use[EB/OL].http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf.
[28]Kurzrock R,Sherman SI,Ball DW,et al.Activity of XL184(Cabozantinib),an oral tyrosine kinase inhibitor,in patients with medullary thyroid cancer[J].J Clin Oncol,2011,29(19):2660-2666.doi:10.1200/JCO.2010.32.4145.
[29]Poulsen A,William A,Blanchard S,et al.Structure-based design of oxygen-linked macrocyclic kinase inhibitors:discovery of SB1518 and SB1578,potent inhibitors of Janus kinase 2(JAK2)and Fms-like tyrosine kinase-3(FLT3)[J].J Comput Aided Mol Des,2012,26(4):437-450.doi:10.1007/s10822-012-9572-z.
[30]EMEA-001621-PIP01-14[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/pips/EMEA-001621-PIP01-14/pip_001217.jsp&mid=WC0b01ac058001d129.
[31]CDER Fast Track Products Approved Since 1998 through June1,2010[EB/OL].http://www.fda.gov/downloads/Drugs/Development Approval Process/How Drugsare Developedand Approved/Drugand Biologic Approval Reports/UCM216527.pdf.
[32]Zarrinkar PP,Gunawardane RN,Cramer MD,et al.AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia(AML)[J].Blood,2009,114(14):2984-2992.doi:10.1182/blood-2009-05-222034.
[33]Lancet JE.New agents:great expectations not realized[J].Best Pract Res Clin Haematol,2013,26(3):269-274.doi:10.1016/j.beha.2013.10.007.
[34]Tentler JJ,Bradshaw-Pierce EL,Serkova NJ,et al.Assessment of the in vivo antitumor effects of ENMD-2076,a novel multitargeted kinase inhibitor,against primary and cell line-derived human colorectal cancer xenograft models[J].Clin Cancer Res,.2010,16(11):2989-2998.doi:10.1158/1078-0432.CCR-10-0325.
[35]Search Orphan Drug Designations and Approvals:Midostaurin[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=306410.
[36]11 studies found for:PLX-3397[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=PLX-3397&Search=Search.
[37]Fletcher GC,Brokx RD,Denny TA,et al.ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action[J].Mol Cancer Ther,2011,10(1):126-137.doi:10.1158/1535-7163.MCT-10-0574.
[38]8 studies found for:ENMD-2076[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=ENMD-2076&Search=Search.
[39]Berdini V,Curry JE,Gallagher NJ,et al.Pharmaceutical Compounds:US,WO/2007/077435(A1)[P/OL].2007-07-12.http://www.freepatentsonline.com/WO2007077435A1.html.
[40]5 studies found for:AT-9283[EB/OL].https://clinicaltrials.gov/ct2/results/s=b&flds=i&flds=f&flds=j&submit_fld_opt=on&term=AT-9283&show_flds=Y.
[41]Heinrich MC,Griffith D,Mc Kinley A,et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors[J].Clin Cancer Res,2012,18(16):4375-4384.doi:10.1158/1078-0432.CCR-12-0625.
[42]10 studies found for:Crenolanib[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=Crenolanib&Search=Search.
[43]Heise CC,Hollenbach P,Menezes D,et al.Treatment of Melanoma:Switzerland,WO/2008/112509(A1)[P/OL].2008-09-18.http://www.freepatentsonline.com/WO2008112509A1.html.
[44]47 studies found for:Dovitinib[EB/OL].https://clinicaltrials.gov/ct2/resultsterm=Dovitinib&Search=Search.
[45]Famitinib malate VS Sunitinib malate(Sutent)[EB/OL].http://blog.sina.com.cn/s/blog_69ecff150100nf2r.html.[苹果酸法米替尼VS苹果酸舒尼替尼(索坦)[EB/OL].http://blog.sina.com.cn/s/blog_69ecff150100nf2r.html.]
[46]Zhang W,Zhou AP,Qin Q,et al.Famitinib in metastatic renal cell carcinoma:a single center study[J].Chin Med J(Engl),2013,126(22):4277-4281.doi:10.3760/cma.j.issn.0366-6999.20131757.
[47]8 studies found for:Famitinib[EB/OL].https://www.clinicaltrials.gov/ct2/resultsterm=Famitinib&Search=Search.
[48]Chan WW,Wise SC,Kaufman MD,et al.Conformational control inhibition of the BCR-ABL1 tyrosine kinase,including the gatekeeper T315I mutant,by the switch-control inhibitor DCC-2036[J].Cancer Cell,2011,19(4):556-568.doi:10.1016/j.ccr.2011.03.003.
[49]Cortes JE,Talpaz M,Kantarjian HM,et al.A Phase 1 study of DCC-2036,a novel oral inhibitor of BCR-ABL kinase,in patients with philadelphia chromosome positive(Ph+)leukemias including patients with T315I mutation[J].Blood(ASH Annual Meeting Abstracts)2011;118(21):Abstract 601.
[50]Eriksson A,Kalushkova A,Jarvius M,et al.AKN-028induces cell cycle arrest,downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia[J].Biochem Pharmacol,2014,87(2):284-291.doi:10.1016/j.bcp.2013.10.022.
[51]Trial record 1 of 1 for:AKN-028[EB/OL].https://clinicaltrials.gov/ct2/show/NCT01573247term=AKN-028&rank=1.
[52]Stone RM,Fischer T,Paquette R,et al.Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia[J].Leukemia,2012,26(9):2061-2068.doi:10.1038/leu.2012.115.
[53]Trial record 1 of 1 for:NCT02014558[EB/OL].https://www.clinicaltrials.gov/ct2/show/NCT02014558term=NCT02014558&rank=1.
[54]William AD,Lee AC,Goh KC,et al.Discovery of kinase spectrum selective macrocycle(16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene(SB1317/TG02),a potent inhibitor of cyclin dependent kinases(CDKs),Janus kinase 2(JAK2),and fms-like tyrosine kinase-3(FLT3)for the treatment of cancer[J].J Med Chem,2012,55(1):169-196.doi:10.1021/jm201112g.
[55]álvarez-Fernández S,Ortiz-Ruiz MJ,Parrott T,et al.Potent antimyeloma activity of a novel ERK5/CDK inhibitor[J].Clin Cancer Res,2013,19(10):2677-2687.doi:10.1158/1078-0432.CCR-12-2118.
[56]Younes A,Romaguera J,Fanale M,et al.Phase I study of a novel oral Janus kinase 2 inhibitor,SB1518,in patients with relapsed lymphoma:evidence of clinical and biologic activity in multiple lymphoma subtypes[J].J Clin Oncol,2012,30(33):4161-4167.doi:10.1200/JCO.2012.42.5223.
[57]Furqan M,Mukhi N,Lee B,et al.Dysregulation of JAKSTAT pathway in hematological malignancies and JAK inhibitors for clinical application[J].Biomark Res,2013,1(1):5.doi:10.1186/2050-7771-1-5.
[58]Search Orphan Drug Designations and Approvals:Pacritinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=245607.
[59]Cortes JE,Kantarjian H,Foran JM,et al.Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMSlike tyrosine kinase 3-internal tandem duplication status[J].J Clin Oncol,2013,31(29):3681-3687.doi:10.1200/JCO.2013.48.8783.
[60]Ramsingh G,Westervelt P,Mc Bride A,et al.Phase I study of cladribine,cytarabine,granulocyte colony stimulating factor(CLAG regimen)and midostaurin and all-trans retinoic acid in relapsed/refractory AML[J].Int J Hematol,2014,99(3):272-278.doi:10.1007/s12185-014-1503-4.
[61]EU/3/04/214[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/orphans/2009/11/human_orphan_000072.jsp&mid=WC0b01ac058001d12b.
[62]Search Orphan Drug Designations and Approvals:Midostaurin[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=285909.
[63]Phase I data suggest PLX3397 is a potential therapy for patients with advanced pigmented villonodular synovitis[EB/OL].Memorial Sloan Kettering Cancer Center,[2014-05-14].http://www.mskcc.org/pressroom/press/phase-i-data-suggest-plx3397-potential-therapy-patients-advanced-pigmented-villonodular-synovitis.
[64]Search Orphan Drug Designations and Approvals:[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=419913.
[65]Trial record 1 of 8 for:ENMD-2076[EB/OL].https://www.clinicaltrials.gov/ct2/show/NCT01914510term=ENMD-2076&rank=1.
[66]Diamond JR,Bastos BR,Hansen RJ,et al.Phase I safety,pharmacokinetic,and pharmacodynamic study of ENMD-2076,a novel angiogenic and Aurora kinase inhibitor,in patients with advanced solid tumors[J].Clin Cancer Res,2011,17(4):849-860.doi:10.1158/1078-0432.CCR-10-2144.
[67]Search Orphan Drug Designations and Approvals:2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+)tartrate salt[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=437214.
[68]Lewis NL,Lewis LD,Eder JP,et al.Phase I study of the safety,tolerability,and pharmacokinetics of oral CP-868,596,a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers[J].J Clin Oncol,2009,27(31):5262-5269.doi:10.1200/JCO.2009.21.8487.
[69]Search Orphan Drug Designations and Approvals:Crenolanib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=363812.
[70]Search Orphan Drug Designations and Approvals:Crenolanib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=320910.
[71]Search Orphan Drug Designations and Approvals:Crenolanib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=335911.
[72]Kim KB,Chesney J,Robinson D,et al.Phase I/II and pharmacodynamic study of dovitinib(TKI258),an inhibitor of fibroblast growth factor receptors and VEGF receptors,in patients with advanced melanoma[J].Clin Cancer Res,2011,17(23):7451-7461.doi:10.1158/1078-0432.CCR-11-1747.
[73]Search Orphan Drug Designations and Approvals:Dovitinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=210105.
[74]Search Orphan Drug Designations and Approvals:dovitinib[EB/OL].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Number=388012.
[75]Cao J,Zhang J,Wang ZH,et al.Hypothyroidism as a potential biomarker of efficacy of famitinib,a novel VEGFR2 inhibitor in metastatic breast cancer[C].6th Asian Oncology Summit and10th Annual Conference of the Organisation for Oncology and Translational Research,Eur J Cancer,2014,50(Suppl 4):e1.
[76]Chiang AK,Mak NK,Ng WT.Translational research in nasopharyngeal carcinoma[J].Oral Oncol,2014,50(5):345-352.doi:10.1016/j.oraloncology.2013.11.005.
[77]Eriksson A,Hermanson M,Wickstrm M,et al.The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia[J].Blood Cancer J,2012,2:e81.doi:10.1038/bcj.2012.28.
[78]Poulsen A,William A,Blanchard S,et al.Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02,a potent inhibitor of cyclin dependant kinases(CDKs),Janus kinase 2(JAK2),and Fms-like tyrosine kinase-3(FLT3)[J].J Mol Model,2013,19(1):119-130.doi:10.1007/s00894-012-1528-7.
[79]Arkenau HT,Plummer R,Molife LR,et al.A phase I dose escalation study of AT9283,a small molecule inhibitor of aurora kinases,in patients with advanced solid malignancies[J].Ann Oncol,2012,23(5):1307-1313.doi:10.1093/annonc/mdr451.